{
    "clinical_study": {
        "@rank": "112561", 
        "arm_group": {
            "arm_group_label": "Two-Period Fixed-Sequence Arm", 
            "arm_group_type": "Experimental", 
            "description": "This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991."
        }, 
        "brief_summary": {
            "textblock": "A single 125 mg oral dose of the investigational compound PD-0332991 will be administered\n      alone and after steady-state dosing of tamoxifen to determine if coadministration of\n      tamoxifen alters the plasma pharmacokinetics of PD-0332991 in healthy male volunteers."
        }, 
        "brief_title": "A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male between the ages of 18 and 55 years of age inclusive\n\n          -  Body mass index (BMI) between 17.5 and 30.5 kg/m2\n\n          -  Willing and able to comply with all scheduled visits, treatment plan, laboratory\n             tests, and other study procedures\n\n        Exclusion Criteria:\n\n          -  a positive urine drug screen\n\n          -  a supine systolic blood pressure >140 mm Hg, or diastolic blood pressure >90 mm H.\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821066", 
            "org_study_id": "A5481026"
        }, 
        "intervention": [
            {
                "arm_group_label": "Two-Period Fixed-Sequence Arm", 
                "description": "PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.", 
                "intervention_name": "PD-0332991 alone", 
                "intervention_type": "Drug", 
                "other_name": "PD-0332991, palbociclib"
            }, 
            {
                "arm_group_label": "Two-Period Fixed-Sequence Arm", 
                "description": "On Days 1-4 of Period 2, tamoxifen is administered daily as  60 mg oral doses (using three 20mg tablets).", 
                "intervention_name": "Tamoxifen 60 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Two-Period Fixed-Sequence Arm", 
                "description": "On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.", 
                "intervention_name": "Tamoxifen 20 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Two-Period Fixed-Sequence Arm", 
                "description": "PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.", 
                "intervention_name": "PD-0332991 combination", 
                "intervention_type": "Drug", 
                "other_name": "PD-0332991, palbociclib"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tamoxifen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PD-0332991", 
            "palbociclib", 
            "tamoxifen", 
            "drug-drug interaction (DDI) study"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481026&StudyName=A%20Study%20To%20Determine%20If%20Coadministration%20Of%20Tamoxifen%20Alters%20The%20Extent%20Or%20Rate%20Of%20Palbociclib%20%28PD-0332991%29%20Absorption%20Or%20Elimination%"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study Of The Effect Of Multiple Doses Of Tamoxifen On PD-0332991 Pharmacokinetics In Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
            "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PD-0332991", 
            "safety_issue": "No", 
            "time_frame": "0-144 hrs post PD-0332991 dose"
        }, 
        "removed_countries": {
            "country": "Belgium"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821066"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "0-144 hrs post PD-0332991 dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "0-144 hrs post PD-0332991 dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "0-144 hrs post PD-0332991 dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "0-144 hrs post PD-0332991 dose"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "0-144 hrs post PD-0332991 dose"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "0-144 hrs post PD-0332991 dose"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin) of tamoxifen", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5, 12, 21, 22, and 28 of Period 2"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin) of 4-hydroxytamoxifen", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5, 12, 21, 22, and 28 of Period 2"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin) of N-desmethyltamoxifen", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5, 12, 21, 22, and 28 of Period 2"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin) of endoxifen", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5, 12, 21, 22, and 28 of Period 2"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}